HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir

Antimicrob Agents Chemother. 2013 Feb;57(2):1053-6. doi: 10.1128/AAC.01668-12. Epub 2012 Nov 26.

Abstract

Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Drug Resistance, Viral / genetics
  • Drug Therapy, Combination
  • Female
  • Genetic Variation
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • HIV Reverse Transcriptase / genetics*
  • HIV-1 / classification
  • HIV-1 / drug effects
  • HIV-1 / enzymology
  • HIV-1 / genetics
  • Humans
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Organophosphonates / therapeutic use*
  • RNA-Directed DNA Polymerase / genetics
  • Reverse Transcriptase Inhibitors / pharmacology
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Tenofovir

Substances

  • Anti-HIV Agents
  • Organophosphonates
  • Reverse Transcriptase Inhibitors
  • Tenofovir
  • reverse transcriptase, Human immunodeficiency virus 1
  • HIV Reverse Transcriptase
  • RNA-Directed DNA Polymerase
  • Adenine

Associated data

  • GENBANK/KC218938
  • GENBANK/KC222012